Related Experiment Video
Updated: Jun 26, 2026
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
Published on: January 20, 2023
Unique challenges in clinical trials in traumatic brain injury
1Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom. dkm13@wbic.cam.ac.uk
Abstract:
Clinical trials in traumatic brain injury have shown little success in providing an evidence base for the introduction of successful new therapies into clinical practice. In addition to the problems that are common to all such studies in critical illness, trials in traumatic brain injury are complicated by the extremely short temporal window for intervention, failure of many candidate drugs to cross the blood-brain barrier, ethical and regulatory obstacles associated with research in subjects who cannot provide consent, the tendency to use small sample sizes in anticipation of unrealistic treatment benefits, and difficulty in translating experimental success into clinical practice. This article reviews the potential causes of these problems and suggests some solutions. These include the changes in regulatory frameworks that are making waived consent an acceptable strategy once more, and an increasing trend toward appropriately large trials. Other encouraging developments include the increasing use of human experimental medicine strategies before phase III trials to assess blood-brain barrier penetration and dose ranging, and provide proof of concept and proof of mechanism. Novel approaches to trial design, such as sliding dichotomy, coupled with robust outcome prediction models, can increase statistical power and improve trial design.
Insights
Clinical trials for traumatic brain injury (TBI) face challenges like short intervention windows and drug delivery. Solutions include larger trials, waived consent, and improved experimental medicine strategies for better TBI therapies.
Area of Science:
- Neuroscience
- Clinical Research
- Pharmacology
Background:
- Traumatic brain injury (TBI) clinical trials have yielded limited success in establishing evidence-based therapies.
- Numerous challenges impede TBI research, including narrow therapeutic windows, blood-brain barrier penetration issues, and ethical considerations for non-consenting patients.
Purpose of the Study:
- To review the obstacles encountered in traumatic brain injury (TBI) clinical trials.
- To propose potential solutions and outline advancements that could improve the success rate of TBI therapeutic development.
Main Methods:
- Review of existing literature on challenges in critical care and TBI clinical trials.
- Analysis of emerging strategies in regulatory frameworks, trial design, and preclinical/early-phase clinical assessments.
Main Results:
- Identified key issues: short intervention times, poor blood-brain barrier penetration, consent challenges, small sample sizes, and translation difficulties.
- Highlighted solutions: revised regulatory frameworks (e.g., waived consent), larger trial designs, and enhanced human experimental medicine (HEM) approaches.
Conclusions:
- Advancements in regulatory flexibility and trial methodologies offer promising avenues for improving TBI research.
- Integrating HEM strategies for assessing drug efficacy and employing novel trial designs can enhance statistical power and clinical translation for TBI treatments.
